PT  - JOURNAL ARTICLE
AU  - Fitzgerald, Kathryn C.
AU  - Mecoli, Christopher A.
AU  - Douglas, Morgan
AU  - Harris, Samantha
AU  - Aravidis, Berna
AU  - Albayda, Jemima
AU  - Sotirchos, Elias S.
AU  - Hoke, Ahmet
AU  - Orbai, Ana-Maria
AU  - Petri, Michelle
AU  - Christopher-Stine, Lisa
AU  - Baer, Alan N.
AU  - Paik, Julie J.
AU  - Adler, Brittany L.
AU  - Tiniakou, Eleni
AU  - Timlin, Homa
AU  - Bhargava, Pavan
AU  - Newsome, Scott D.
AU  - Venkatesan, Arun
AU  - Chaudhry, Vinay
AU  - Lloyd, Thomas E.
AU  - Pardo, Carlos A.
AU  - Stern, Barney J.
AU  - Lazarev, Mark
AU  - Truta, Brindusa
AU  - Saidha, Shiv
AU  - Chen, Edward S.
AU  - Sharp, Michelle
AU  - Gilotra, Nisha
AU  - Kasper, Edward K.
AU  - Gelber, Allan C.
AU  - Bingham, Clifton O.
AU  - Shah, Ami A.
AU  - Mowry, Ellen M.
TI  - RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES
AID  - 10.1101/2021.02.03.21251069
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.03.21251069
4099  - http://medrxiv.org/content/early/2021/02/05/2021.02.03.21251069.short
4100  - http://medrxiv.org/content/early/2021/02/05/2021.02.03.21251069.full
AB  - Background People with autoimmune or inflammatory conditions who take immunomodulatory/suppressive medications may have a higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences.Objective Assess whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterize pandemic-associated changes to care.Design Longitudinal registry studyParticipants 4666 individuals with autoimmune or inflammatory conditions followed by specialists in neurology, rheumatology, cardiology, pulmonology or gastroenterology at Johns HopkinsMeasurements Periodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcareResults A total of 265 (5.6%) developed COVID-19 over 9 months of follow-up (April-December 2020). Patient characteristics (age, race, comorbidity, medication exposure) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in multivariable models incorporating behavior and other potential confounders (OR: 1.43; 95%CI: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95%CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95%CI: 1.24, 2.28), and chronic kidney disease (OR: 1.76; 95%CI: 1.04, 2.97) were each associated with higher odds of COVID-19. Pandemic-related disruption to care was common. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions. Individuals experiencing changes to employment or income were at highest odds of care disruption.Limitations Results may not be generalizable to all patients with autoimmune or inflammatory conditions. Information was self-reported.Conclusions Exposure to glucocorticoids may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKCF is supported by 1K01MH121582-01 from NIH/NIMH and TA-1805-31136 from the National MS Society (NMSS). CAM is supported by K23AR075898-02 from NIH/NIAMS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from the Institutional Review Board at Johns Hopkins Medical Institutions.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data used for this study may be available from the corresponding author on reasonable request, with the proper data sharing agreements in place.